| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
149,990,000 |
| Market
Cap: |
137.98(M) |
| Last
Volume: |
394,168 |
Avg
Vol: |
183,701 |
| 52
Week Range: |
$0.9199 - $0.9199 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Lineage Cell Therapeutics is a clinical-stage biotechnology company developing cell therapies. Co. has several allogeneic cell therapy programs in development: OpRegen®, a retinal pigment epithelium cell replacement therapy for the treatment of advanced dry age-related macular degeneration with geographic atrophy; OPC1, an oligodendrocyte progenitor cell therapy for spinal cord injuries; VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells; and other product candidates in preclinical development covering a range of therapeutic areas and target tissues or organs. Co. has rights to HyStem, a patented biomaterial that mimics naturally occurring extracellular matrix.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
6,826,925 |
6,836,925 |
6,836,925 |
6,836,925 |
| Total Buy Value |
$7,100,002 |
$7,110,902 |
$7,110,902 |
$7,110,902 |
| Total People Bought |
2 |
3 |
3 |
3 |
| Total Buy Transactions |
3 |
4 |
4 |
4 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Samuel George A. Iii |
General Counsel/Secretary |
• – – |
2024-02-11 |
4 |
D |
$1.08 |
$2,689 |
D/D |
(2,490) |
7,184 |
|
- |
|
| Samuel George A. Iii |
General Counsel/Secretary |
• – – |
2024-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,076 |
9,674 |
|
- |
|
| Culley Brian M |
President and CEO |
• • – |
2024-02-11 |
4 |
D |
$1.08 |
$13,830 |
D/D |
(12,806) |
144,842 |
|
- |
|
| Culley Brian M |
President and CEO |
• • – |
2024-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,249 |
157,648 |
|
- |
|
| Bailey Don M |
Director |
– • – |
2024-02-08 |
4 |
B |
$1.04 |
$100,001 |
I/I |
96,155 |
158,801 |
2.1 |
- |
|
| Bradsher Neal C |
Director |
– • • |
2024-02-06 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
41,666,255 |
2.17 |
- |
|
| Bradsher Neal C |
Director |
– • • |
2024-02-06 |
4 |
B |
$1.04 |
$7,000,001 |
D/D |
6,730,770 |
41,666,255 |
3.92 |
- |
|
| Jayasuriya Anula |
Director |
– • – |
2023-12-29 |
4 |
B |
$1.09 |
$10,900 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| Culley Brian M |
President and CEO |
• • – |
2023-02-11 |
4 |
D |
$1.35 |
$17,204 |
D/D |
(12,744) |
126,399 |
|
- |
|
| Culley Brian M |
President and CEO |
• • – |
2023-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,249 |
139,143 |
|
- |
|
| Hogge Gary S. |
SVP,Clinical & Medical Affairs |
• – – |
2023-02-11 |
4 |
D |
$1.35 |
$7,169 |
D/D |
(5,310) |
7,710 |
|
- |
|
| Hogge Gary S. |
SVP,Clinical & Medical Affairs |
• – – |
2023-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,020 |
13,020 |
|
- |
|
| Samuel George A. Iii |
General Counsel/Secretary |
• – – |
2023-02-11 |
4 |
D |
$1.35 |
$3,345 |
D/D |
(2,478) |
3,598 |
|
- |
|
| Samuel George A. Iii |
General Counsel/Secretary |
• – – |
2023-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,076 |
6,076 |
|
- |
|
| Culley Brian M |
President and CEO |
• • – |
2022-06-30 |
4 |
D |
$1.58 |
$8,442 |
D/D |
(5,343) |
107,894 |
|
- |
|
| Culley Brian M |
President and CEO |
• • – |
2022-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,450 |
113,237 |
|
- |
|
| Culley Brian M |
President and CEO |
• • – |
2022-03-31 |
4 |
B |
$1.53 |
$9,792 |
D/D |
6,400 |
97,787 |
2.81 |
- |
|
| Culley Brian M |
President and CEO |
• • – |
2022-03-31 |
4 |
D |
$1.54 |
$8,228 |
D/D |
(5,343) |
91,387 |
|
- |
|
| Culley Brian M |
President and CEO |
• • – |
2022-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,450 |
96,730 |
|
- |
|
| Amin Dipti |
Director |
– • – |
2022-03-28 |
4 |
B |
$1.63 |
$57,050 |
D/D |
35,000 |
35,000 |
2.39 |
- |
|
| Culley Brian M |
President and CEO |
• • – |
2022-03-25 |
4 |
B |
$1.38 |
$7,245 |
D/D |
5,250 |
81,280 |
2.81 |
- |
|
| Bradsher Neal C |
Director |
– • • |
2022-03-25 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
34,935,485 |
2.17 |
- |
|
| Bradsher Neal C |
Director |
– • • |
2022-03-25 |
4 |
B |
$1.44 |
$678,022 |
D/D |
470,000 |
34,935,485 |
3.92 |
- |
|
| Mulroy Michael H. |
Director |
– • – |
2022-03-24 |
4 |
B |
$1.40 |
$9,800 |
D/D |
7,000 |
258,555 |
2.39 |
- |
|
| Bradsher Neal C |
Director |
– • • |
2022-03-24 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
34,465,485 |
2.17 |
- |
|
194 Records found
|
|
Page 1 of 8 |
|
|
